Eco-Friendly Lung Inhalers
The EU Panel Approves of AstraZeneca's Smoker's Lung Inhaler
Debra John — July 25, 2025
A lung inhaler developed by AstraZeneca has received support from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its environmentally improved design. The inhaler, known as Trixeo Aerosphere (or Breztri Aerosphere in some regions), is used in the treatment of chronic obstructive pulmonary disease (COPD)—a condition often linked to long-term smoking, air pollution, and occupational exposure.
In this updated version, the inhaler uses a next-generation propellant developed by Honeywell that delivers medication effectively while significantly reducing environmental impact. Unlike traditional propellants, the new medical-grade gas has a much lower global warming potential, aligning with AstraZeneca’s broader commitment to sustainable healthcare innovation.
The CHMP’s recommendation highlights the potential of eco-friendly pharmaceutical technologies to reduce carbon emissions while maintaining high standards of patient care and respiratory treatment effectiveness across Europe.
